VRCA
Price
$1.56
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
9 days until earnings call
ZYME
Price
$13.24
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
Ad is loading...

VRCA vs ZYME

Header iconVRCA vs ZYME Comparison
Open Charts VRCA vs ZYMEBanner chart's image
Verrica Pharmaceuticals
Price$1.56
Change-$0.00 (-0.00%)
Volume$430.33K
CapitalizationN/A
Zymeworks
Price$13.24
Change-$0.00 (-0.00%)
Volume$639.75K
CapitalizationN/A
View a ticker or compare two or three
VRCA vs ZYME Comparison Chart
Loading...
VRCA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
VRCA vs. ZYME commentary
Oct 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VRCA is a Buy and ZYME is a Buy.

COMPARISON
Comparison
Oct 30, 2024
Stock price -- (VRCA: $1.56 vs. ZYME: $13.24)
Brand notoriety: VRCA and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: VRCA: 44% vs. ZYME: 84%
Market capitalization -- VRCA: $61.87M vs. ZYME: $882.41M
VRCA [@Biotechnology] is valued at $61.87M. ZYME’s [@Biotechnology] market capitalization is $882.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VRCA’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • VRCA’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZYME is a better buy in the long-term than VRCA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

VRCA’s TA Score shows that 3 TA indicator(s) are bullish while ZYME’s TA Score has 3 bullish TA indicator(s).

  • VRCA’s TA Score: 3 bullish, 4 bearish.
  • ZYME’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, VRCA is a better buy in the short-term than ZYME.

Price Growth

VRCA (@Biotechnology) experienced а -0.64% price change this week, while ZYME (@Biotechnology) price change was +0.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

VRCA is expected to report earnings on Feb 27, 2025.

ZYME is expected to report earnings on May 08, 2023.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZYME($882M) has a higher market cap than VRCA($61.9M). ZYME YTD gains are higher at: 27.430 vs. VRCA (-78.689). VRCA has higher annual earnings (EBITDA): -77.18M vs. ZYME (-105.32M). ZYME has more cash in the bank: 330M vs. VRCA (31.9M). ZYME has less debt than VRCA: ZYME (20.1M) vs VRCA (46.3M). ZYME has higher revenues than VRCA: ZYME (62.7M) vs VRCA (13.9M).
VRCAZYMEVRCA / ZYME
Capitalization61.9M882M7%
EBITDA-77.18M-105.32M73%
Gain YTD-78.68927.430-287%
P/E RatioN/AN/A-
Revenue13.9M62.7M22%
Total Cash31.9M330M10%
Total Debt46.3M20.1M230%
FUNDAMENTALS RATINGS
VRCA vs ZYME: Fundamental Ratings
VRCA
ZYME
OUTLOOK RATING
1..100
2179
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
9638
P/E GROWTH RATING
1..100
10079
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZYME's Valuation (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRCA (95). This means that ZYME’s stock grew somewhat faster than VRCA’s over the last 12 months.

ZYME's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as VRCA (100). This means that ZYME’s stock grew similarly to VRCA’s over the last 12 months.

ZYME's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as VRCA (100). This means that ZYME’s stock grew similarly to VRCA’s over the last 12 months.

ZYME's Price Growth Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for VRCA (96). This means that ZYME’s stock grew somewhat faster than VRCA’s over the last 12 months.

ZYME's P/E Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as VRCA (100). This means that ZYME’s stock grew similarly to VRCA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
VRCAZYME
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
VRCA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.732.16
+10.50%
GameStop Corp
BTC.X69907.7600001978.460900
+2.91%
Bitcoin cryptocurrency
AAPL233.401.99
+0.86%
Apple
SPY580.831.79
+0.31%
SPDR® S&P 500® ETF Trust
TSLA262.51-6.68
-2.48%
Tesla

VRCA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with TCBP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then TCBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
+3.31%
TCBP - VRCA
41%
Loosely correlated
+6.25%
SCPX - VRCA
38%
Loosely correlated
+1.39%
DNA - VRCA
33%
Poorly correlated
+1.35%
THRD - VRCA
29%
Poorly correlated
+10.27%
SLNO - VRCA
29%
Poorly correlated
+0.71%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with BEAM. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
+2.40%
BEAM - ZYME
48%
Loosely correlated
+3.71%
INZY - ZYME
45%
Loosely correlated
-0.21%
NKTX - ZYME
44%
Loosely correlated
+3.90%
CRSP - ZYME
43%
Loosely correlated
+4.96%
ABSI - ZYME
43%
Loosely correlated
+5.41%
More